Adverum reveals positive results from Phase 1 trial of ADVM-022
Category: #health  By Mateen Dalal  Date: 2019-09-14
  • share
  • Twitter
  • Facebook
  • LinkedIn

Adverum reveals positive results from Phase 1 trial of ADVM-022

The drug was well tolerated and was safe, and has shown the capacity to improve the treatment paradigm for patients with wet AMD.

Adverum Biotechnologies, Inc., a company that develops medical therapies for ocular and rare diseases, recently announced the demonstration of positive 24-week clinical data. Apparently, the data was obtained from the initial cohort of patients treated with a one-time IVT (intravitreal) dosage of ADVM-022 in the OPTIC phase 1 clinical study in wet AMD (age-related macular degeneration).

According to reliable sources, patients who participated in this cohort gained progress in retinal anatomy and vision maintenance, without the requirement of anti-VEGF rescue injections, after a one-time IVT dose of the drug.

Reportedly, these patients earlier needed numerous anti-VEGF injections to maintain functional vision and to regulate their wet AMD. Moreover, the data is slated to be presented in September, by Szilárd Kiss, M.D., retinal specialist & the presenter for the meeting, at a podium presentation during the Retina Society 2019 Annual Meeting.

Speaking on the move, Kiss said that generally people with wet AMD need repeated anti-VEGF injections to sustain vision, representing a significant treatment load which often ends in vision loss due to lack of treatment. A long-term anti-VEGF treatment would significantly fulfill the clinical need for these patients.

He added that the material frequent injections to on ADVM-022 are promising, as they successfully show that a one-time gene therapy treated by IVT injection has the capacity to improve the treatment paradigm for patients with wet AMD and offer sustained efficacy.

As for Aaron Osborne, MBBS, Chief Medical Officer, Adverum, the company is happy to declare that there was no need for the rescue injections in this cohort of patients through 24 weeks. He claims that patient earlier needed numerous injections to prevent vision loss. Morever, a single injection of ADVM-022 resulted in constant anatomical vision maintenance and advancements.

Source Credit: http://investors.adverum.com/news-releases/news-release-details/adverum-biotechnologies-reports-positive-24-week-data-first

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

Mateen has completed his Bachelor’s degree in electronics and telecommunication engineering, post which he lent his proficiency to the industry, working as a quality and test engineer. Drawn intricately toward the field of content creation however, Mateen soon switc...

Read More

More News By Mateen Dalal

NantHealth & NantOmics launch AI platform for subtyping Lung Cancer
NantHealth & NantOmics launch AI platform for subtyping Lung Cancer
By Mateen Dalal

NantHealth, Inc., a personalized, evidence-based, next-generation healthcare company and NantOmics, LLC, one of the leading companies in molecular analysis, have reportedly launched an innovative AI platform for assisting pathologists in image-based ...

Air France-KLM & JAL make bids to purchase stake in Malaysia Airlines
Air France-KLM & JAL make bids to purchase stake in Malaysia Airlines
By Mateen Dalal

Air France–KLM S.A., one of the leading global air transport players, has reportedly made a proposal to invest in Malaysia Airlines and gain around 49 percent stake. Japan Airlines (JAL) is also looking to acquire a 25 percent stake in Mal...

Accenture opens innovation center in South Beach Road office
Accenture opens innovation center in South Beach Road office
By Mateen Dalal

Accenture, an Irish multinational professional services company, has recently opened a global innovation center within the Accenture’s office at South Beach Road, which is supported by EDB (Economic Development Board) in Singapore. It will pro...